Analyst spotlights a compelling commercial future ahead for Sorrento’s ZTlido in post-herpetic neuralgia.
Ram Selvaraju slashes his target to $8 on slower Trulance ramp.
H.C.
Protalix Biotherapeutics Inc (NYSEMKT:PLX) investors are getting skittish today, sending shares on a roughly 5% whirl down despite the biotech firm posting a …
Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech firm released second-quarter financial results- a quarter that …
Ocular Therapeutix Inc (NASDAQ:OCUL) shares are sliding almost 5% today on the heels of the biotech firm’s President and CEO Antony Mattessich new …
Last week, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) excited investors with the news that its drug Trulance, a treatment approved in the indication of Chronic …
Believing Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) odds in the IBS-C competitive arena just got better, Rodman & Renshaw analyst Ram Selvaraju reiterates a Buy …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares are rising almost 3% today after the biotech firm made waves filing the supplemental New Drug Application (sNDA) …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are sinking almost 5% following the release of financial guidance that paints a murky picture for the …